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Primary sclerosing cholangitis (PSC) is a chronic in· 
flammatory disease of the liver that is characterized by 
progressive cholestasis and the development of second· 
ary biliary cirrhosis. There is no widely recognized ther· 
apy for this disease, although anti-inflammatory agents 
(steroids), immunosuppressive agents (methotrexate), 
anti·fibrotics (colchicine), and choleretic agents (ursode· 
oxycholic acid) have been used in various small series. In 
the present study, Tacrolimus (FK 506), a new and 
powerful immunosuppressive macrolide antibiotic, has 
been used to treat 10 patients with PSC. Each subject 
had a liver biopsy, ERCP with visualization of the intra-
and extrahepatic biliary tree, and a panel of hematolog. 
ical, serological, and biochemical laboratory tests before 
the initiation of the FK 506 therapy. The FK 506 was 
administered orally at 12·h intervals and was monitored 
by serial plasma FK 506 trough levels. After 360 days of 
treatment, the median serum bilirubin level was reduced 
by 75%, and the serum alkaline phosphatase was reo 
duced by 70%. Moreover, the serum ALT and AST 
levels were reduced by 80 and 86%, respectively. No 
change in the serum level of BUN and creatinine levels 
occurred as a consequence of the FK 506 treatment. 
These data demonstrate that: 1) FK 506 can be used to 
treat PSC; 2) the response to FK 506 by patients with 
PSC is rapid; and, 3) no adverse effect on the serum 
BUN and creatinine levels was observed. It is anticipated 
that FK 506 will become an important agent for the 
treatment of patients with PSC because of its powerful 
immunosuppressive activity. 
INTRODUCTION 
Primary sclerosing cholangitis (pSC) is a chronic inflam-
matory disorder of the biliary tree that is characterized by a 
focal, albeit diffuse, destruction of the large- and medium-
sized bile ducts (1-11). The disease is characterized patho-
physiologically by cholestasis (I, 2). Endoscopically and 
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histologically, biliary strictures and diverticula characterize 
the disease process (8-11). 
The specific etiology of PSC is unknown, although be-
cause of its association with inflammatory bowel disease, 
especially ulcerative colitis but also 'Crohn's colitis and 
RIA antigens B8, Dr3, and DrBW52, it is thought to be a 
disease of disordered immunity (12-21). As such, a variety 
of pharmacological agents directed at modifying the im-
mune response have been used to treat PSC. These include 
antibiotics, bile acid absorbants, glucocorticoids, immuno-
suppressive agents (azathioprine, methotrexate, and d-pen-
icillamine), and choleretic agents (cheno- and ursodeoxy-
cholic acid), the latter two of which may also modulate the 
expression of RIA antigens on hepatobiliary epithelial cells 
(22-34). In advanced cases, liver transplantation has been 
used as a therapy (35-36). Moreover, resection of the dam-
aged colon in cases of ulcerative colitis has been used, albeit 
unsuccessfully, to halt or ameliorate disease progression 
(37). 
The present open-label preliminary study was initiated to 
investigate the efficacy and potential toxicity of Tacrolimus 
(FK 506), a powerful new macrolide antibiotic-possessing 
immunosuppressive activity, as a therapeutic agent for the 
treatment of PSC. 
METIIODS 
Subjects 
A total of 10 subjects with a documented diagnosis of 
PSC were studied. Each had either an ERCP- or percutane-
ous transhepatic cholangiogram (PTHC)-confirmed diagno-
sis of PSC supported by the results of a percutaneous liver 
biopsy demonstrating a chronic inflammatory condition of 
the liver, particularly the portal areas with a characteristic 
pericholangiolar inflammatory and fibrotic reaction (11. 12). 
Pretherapy evaluation 
Each subject underwent a thorough pretherapy evaluation 
consisting of the following studies: 
1. Complete blood count (CBC) with platelet count. 
2. A panel of liver injury and function parameters to 
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include total bilirubin, ALT, AST, alkaline phos-
phatase (alk phos), -y glutamyl transpeptidase (-yGTP), 
a serum protein electrophoresis, and a prothrombin 
time. 
3. An endoscopic retrograde cholangiogram or percuta-
neous ttanshepatic cholangiogram. 
4. A percutaneous liver biopsy for histological evalua-
tion. 
5. A full colonoscopy to include multiple colonic biop-
sies from the ceCum, ascending colon, hepatic flexure, 
transverse colon, splenic flexure, descending colon, 
sigmoid colon, and rectum to define the type and 
extent of any associated inflammatory bowel disease. 
6. HLA typing. 
7. BUN, creatinine, and creatinine clearance determina-
tions. 
8. cr scan of the liver for determination of the hepatic 
volume. 
9. An ultrasound study of the liver, biliary tree, and 
portal and hepatic vessels. 
Patient monitoring 
After the pretherapy evaluation procedures were com-
pleted, each subject was given FK S06 at a starting dose of 
0.07S mg/kg taken orally as two equally divided doses taken 
12 h apart. The initial dose was either increased or decreased 
at 2-wk intervals to achieve a trough serum FK S06 level 
between 0.6 and 1.0 nglml. All FK S06 serum levels were 
obtained after an overnight fast and before the next morn-
ing's dose (38). 
Initially, all subjects were seen weekly (approximately 
four visits), then bi-weekly (2-3 visits), then monthly (2-3 
visits), and finally quarterly, until a l-yr study period was 
completed. At each visit, the following studies were ob-
tained: 
1. CBC with platelet count. 
2. Electrolytes, BUN, creatinine, blood sugar. 
3. A liver injury panel consisting of the serum bilirubin, 
AST, ALT, alk phos, and -yGTP levels. 
4. A serum FK S06 level. 
At the end of a l-yr study period, all of the studies 
performed as part of the prestudy evaluation were repeated. 
All liver biopsies were read blindly by pathologists unaware 
of the source of the biopsy study objectives. 
Ethical approval 
This study was approved by the committee reviewing 
clinical research in human subjects at the University of 
Pittsburgh before its initiation. 
Statistical analysis 
All results are presented as mean values ~ SEM. All data 
were compared using the entry and exit measures. The 
Student's t test and ANOVA were used for the statistical 
analyses. A p value <0.05 was considered to be significant. 
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TABU! 1 
CluJrtJetemlic3 uf the 10 Subjecu StlllMd til Entry 
Parameter MIlD: Range Normal SEM Values 
Age (yr) 31.3 : 4.3· 18-58 NA 
Gender (MIF) 7/3 N/A NA 
White blood count 6.0: 0.7 2.5-10.4 S-10 
(cellslmm') 
Platelet count (cellsl 271: 45 90-621 1SO-300 
mm') 
Total bilirubin (mgldl) 1.8: 0.6 0.9-6.6 <1.1 
AST (lUll) 172: 32 81-453 <32 
ALT (lUll) 258: 57 73-712 <32 
A1k pbos (lUll) 422: 93 190-1233 <125 
yGTP (lUll) 688: 182 210-2634 <35 
BUN (mgldl) 12.8: 1.3 4.1-21 10 
Creatinine (mgldl) 0.9: 0.1 0.4-1.6 <1.2 
Ulcerative colitis (N) 6 NA 
Crobn '5 colitis (N) 2 NA 
Hepatic volume (mi) 1837 : 216 1225: 250 
HLA B8-positive 10 NA NA 
HLA Dr3·positive 10 NA NA 
HLA DrBWS2 10 NA NA 
• Values are means :!: SEM. 
NA, not applicable. 
RESULTS 
A total of 10 subjects were enrolled in this open-label, 
preliminary study evaluating the efficacy and toxicity of FK 
S06 in the treatment of PSc. The demographic information 
in the 10 subjects studied is shown in Table 1. Most were 
male; 60% had co-existent ulcerative colitis, and all were 
positive for HLA antigens B8, Dr3, and DrBWS2. The mean 
hepatic volume of the group was increased by SO% com-
pared with normal values. The mean time required to 
achieve a stable serum level of FK S06 between 0.6 and 1.0 
ng/ml and to maintain renal function at acceptable levels 
was 7.5 ~ 2.S wk. The mean FK dose prescribed on a daily 
basis was 10.5 ~ 2.8 mg/day, whereas the mean daily dose 
on a per kg basis was O.IS ~ 0.04 mg/kg/day. 
Associated with FK S06 treatment, the serum alk phos 
and bilirubin levels fell, as shown in Figure 1. The alk phos 
level declined by more than SO% from a level 3.S times 
nonnal to 1.5 times normal (p < 0.01). The serum bilirubin 
level returned to the normal range (p < 0.01). Figure 2 and 
Table 2 show the data for serum bilirubin, AST, and ALT. 
Both enzymes fell markedly with FK S06 treatment to levels 
just outside and inside the normal range, respectively (p < 
0.01). The BUN level increased minimally, whereas the 
serum creatinine level remained unchanged. The changes in 
the serum BUN and creatinine levels at quarterly intervals 
are shown in Figure 3 along with the plasma FK S06 levels 
and the dose administered. 
No changes in the hepatic volume or ERCP findings were 
observed over the course of the l-yr of FK S06 therapy. 
Similarly, no change in the colonoscopic findings were 
observed over the l-yr course of FK S06 therapy. The 
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FIG. 1. Serum total bilirubin and alk phos levels with increasing time 
through 1 yr on FK 506 in the 10 subjects studied. The points are mean 
values; the brackets represent the SEM. 
c ' 
i i 
250d 
ALl 
I 1\ ~ i ~ \ 
;: Oooi~ \ 
~ '"'r·, y~q 
lOOr I 
L .l. 
I -
50 r .!. --
o C 90 180 270 360 
Time on FK506 (days} 
ASl 
2S0r 
OMM~-
o 
90 180 270 350 
Time on FK506 (oays) 
FIG. 2. Serum AL T and AST levels with increasing time through 1 yr on 
FK 506 in the 10 subjects studied. The points are mean values; the brackets 
represent the SEM. 
patients did report a reduction in pruritis grade (p < 0.05) 
and frequency of bowel movements (p < 0.05) associated 
with the use of FK 506 compared with pre-FK 506 levels. 
When the liver biopsies obtained pre- and post-1 yr of FK 
506 therapy were compared in a blinded fashion, little or no 
statistical difference was seen between the two biopsies. 
Thus, although this was no histological regression, there 
also was no identifiable progression. 
DISCUSSION 
This is the first report on the use of FK 506, a macrolide 
antibiotic isolated from streptomyces tsukubaenis that has 
powerful immunosuppressive activity that has been esti-
mated to be 10-100 times more powerful than cyclosporine 
wben it has been studied in various in vitro assay systems 
assessing T cell functional activity (39). 
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TABU 2 
Initial and J -Yr Clinical Characteristics of tIlL Patients Studied 
Parameters Initial Result I·Yr Result Normal Values 
Total bilirubin (mg/dl) 1.8 ± 0.6 0.7 ± 0.1 <1.1 
AST (lUll) 172 =: 32 35 =: 20 <32 
ALT(IU/I) 258 ± 57 40 ± 15 <32 
AIk phos (UII) 420 =: 93 200 =: 50 <125 
Protime (5) 13.2 ± 1.0 13.0 ± 1.0 11.0 
White blood count 6.0 ± 0.7 6.2 =: 0.8 5-10 
(XIQl) 
Platelets (X 1 Ql) 271:: 45 228 ± 30 150-300 
cr liver volume (ml) 1820 ± 230 1880 ± 210 1000-1500 
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FIG. 3. Serum BUN and creatinine levels in the 10 subjects studied as 
well as the FK 506 dose and plasma levels with increasing time through 1 
yr on FK 506. Values are mean :!: SEM. 
FK 506 has been studied extensively in transplant pa-
tients, including tbose with liver, kidney, and intestinal 
grafts (40-42). In each case, FK 506 has been shown to be 
at least as good, if not better, than cyclosporine at preventing 
allograft rejection (40-42). Unlike cyclosporine, increasing 
doses of FK 506 can be used to treat an acute cellular 
rejection episode (44-47). Moreover, FK 506, unlike cy-
closporine, has been shown to be capable of reversing early 
chronic allograft rejection (44-47) 
These unique advantages of FK 506 and its relative ease 
of administration, coupled with the ability to monitor its 
blood levels and adjust the dosing schedule'as necessary to 
either enhance efficacy or reduce toxicity, have made it a 
particularly attractive agent for the clinical treatment of a 
variety of putative autoimmune diseases. PSC is one of 
these diseases. 
As shown in Figures 1,2, and 3 and in Table 2, FK 506 
has been shown to be very effective at controlling the 
relentless biliary destruction and cholestasis that character-
izes PSC as assessed biocbemically. The serum levels of aIk 
phos. bilirubin, and both aminotransferases fell rapidly to 
either normal or near normal values. 
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FIG. 4. White blood cell counts and platelet counts in the 10 patients 
studied are shown with increasing time through 1 yr on FK 506. Values are 
mean::!: SEM. 
The cost of this improvement in the course of PSC in 
terms of drug toxicity has been mild to nonexistent as shown 
in Figures 3 and 4. Only minor changes in renal function and 
a transient fall in the platelet count were observed in re-
sponse to FK 506 treatment. 
Moreover, the immunosuppressive activity of FK 506 had 
the added advantage, not directly assessed as part of this 
study but nonetheless obvious to the physicians and sur-
geons caring for these patients, that the enhanced control of 
their liver disease was associated with control of underlying 
inflammatory bowel disease. It should be pointed out, how-
ever, that improvement in the various biochemical values 
used to assess hepatic injury may not be adequate in defin-
ing the long term clinical course of a disease such as primary 
sclerosing cholangitis. The effects on survival, the need for 
transplantation, longer term changes on hepatic biopsy, and, 
possibly, changes on cholangiography may all be more 
important parameters to be assessed in future studies. 
Nonetheless, based on this preliminary open-label trial 
evaluating the efficacy of FK 506 in the clinical manage-
ment of PSC, the investigators believe that a randomized 
controlled study comparing FK 506 to ursodeoxycholic acid 
or possibly methotrexate is indicated. These latter two 
agents also have been reported to be efficacious in cases of 
PSC, the former in several small trials and the latter in a trial 
from a single institution. The effects achieved with both of 
these other agents have been assessed primarily on the basis 
of clinical parameters. Nonetheless, based on the evidence 
available, each appears to be somewhat effective. Only by a 
direct comparison, probably as a result of a multi-center 
trial, will the practitioner be able to make a rational choice 
between these new agents. 
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